Voclosporin

Breastfeeding
  • TRADE NAME: Lupkynis (Aurinia Pharmaceuticals)
  • INDICATIONS: Treatment of adult patients with active lupus nephritis (in combination with immunosuppressive therapy)
  • CLASS: Calcineurin inhibitor
  • HALF-LIFE: Approximately 30 hours

FDA APPROVAL DATE: 01/22/2021

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Clarithromycin, CYP3A4 inducers , CYP3A4 inhibitors, Diltiazem, Fluconazole, Itraconazole, Ketoconazole, P-gp substrates, Verapamil


May cause fetal harm. Advise patient not to breastfeed.

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS

INCREASED RISK FOR DEVELOPING MALIGNANCIES AND SERIOUS INFECTIONS WITH VOCLOSPORIN OR OTHER IMMUNOSUPPRESSANTS THAT MAY LEAD TO HOSPITALIZATION OR DEATH


See full prescribing information for complete boxed warning

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.


Page last updated 10/09/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top